Regulatory Setback Tempers ImmunityBio's Rally

ImmunityBio faces FDA rebuke over marketing claims, erasing $2B in value. Yet, Anktiva's 700% revenue surge and 33-country approval reveal underlying operational strength ahead of a critical earnings report.

The biotechnology sector offers little forgiveness for missteps in corporate communications. ImmunityBio learned this lesson acutely in late March when a rebuke from the U.S. Food and Drug Administration (FDA) erased nearly $2 billion in market capitalization. While misleading promotional claims for its cancer drug Anktiva rattled investors, the company's underlying operational progress and global expansion present a surprisingly resilient counter-narrative.

Operational Momentum Continues Unabated

Beyond the recent regulatory turbulence, ImmunityBio's commercial engine continues to fire. The company's key drug, Anktiva, has now gained approval in 33 countries, including the United States, the United Kingdom, and the European Union. This rapid international rollout is translating directly to the financial statements. For the full year 2025, net product revenue surged by 700% to reach $113 million. Concurrently, the firm managed to reduce its selling, general, and administrative expenses from $168.8 million to $150 million.

The clinical development pipeline is also advancing. In early March, ImmunityBio submitted a supplemental Biologics License Application (sBLA) to the FDA for a specific bladder cancer indication. The regulator requested only additional data, notably waiving the requirement for new clinical trials. Furthermore, the crucial QUILT-2.005 study, which involves 366 patients, is now fully enrolled.

A Costly Marketing Misstep

The catalyst for the recent share price decline of over 20% on a monthly basis was a fateful marketing decision. The FDA determined that certain promotional materials from the company were false and misleading. Television advertisements and podcast content had created the impression that the bladder cancer therapy Anktiva could cure or even prevent all types of cancer.

Wall Street's response was swift. On March 24, the stock plummeted 21% after the agency's letter to CEO Richard Adcock became public. Despite this significant setback, the equity remains notably higher for the year-to-date 2026, underscoring the fundamental strength it exhibited prior to the FDA's intervention.

Investor Focus Shifts to Upcoming Results

All eyes are now on the upcoming quarterly presentation scheduled for May 11. Investors will be focused squarely on concrete sales figures. Management must demonstrate that first-quarter 2026 sales volumes for Anktiva have remained stable despite the FDA's action and that the promotional misstep has not derailed operational growth. Market analysts currently anticipate a quarterly loss of $0.07 per share.

The coming report will be a critical test, revealing whether the company's solid commercial foundations can outweigh the substantial reputational damage inflicted by its regulatory stumble.